Panacea Life Sciences Holdings, Inc.
PLSH
$0.07
-$0.05-40.12%
OTC PK
| 03/31/2024 | 12/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 9.98% | 176.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.98% | 176.09% | |||
| Cost of Revenue | -3.95% | 30.72% | |||
| Gross Profit | 17.60% | 13.74% | |||
| SG&A Expenses | -68.36% | 184.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.53% | 54.86% | |||
| Operating Income | 40.20% | -25.03% | |||
| Income Before Tax | 34.53% | -2.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 34.53% | -2.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 34.53% | -2.68% | |||
| EBIT | 40.20% | -25.03% | |||
| EBITDA | 49.12% | -33.78% | |||
| EPS Basic | 33.86% | -2.47% | |||
| Normalized Basic EPS | 31.68% | -21.05% | |||
| EPS Diluted | 33.86% | -2.47% | |||
| Normalized Diluted EPS | 31.68% | -21.05% | |||
| Average Basic Shares Outstanding | -0.99% | 0.24% | |||
| Average Diluted Shares Outstanding | -0.99% | 0.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||